MYSM1 and breast carcinoma: MYSM1, a deubiquitinase highly expressed in breast cancer samples, was shown to regulate ERα activity, and its depletion in xenograft models reduced breast cancer cell proliferation while enhancing sensitivity to anti-estrogen therapies [19].